Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis.
constipation
neuroendocrine tumors
ovarian strumal carcinoid
peptide YY
teratomas
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
24
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Ovarian strumal carcinoid is a rare tumor in which thyroid (struma) and carcinoid components coexist. The disease is generally considered to be a borderline malignancy, however, cases with metastatic disease have been described. No data in the literature are available to guide diagnosis and therapy. We performed a pooled analysis and a systematic review of histopathological-confirmed strumal carcinoid cases published in the literature using the following keywords: "strumal carcinoid of the ovary", "strumal carcinoid case report". A case of strumal carcinoid tumor diagnosed and followed-up at the Medical Oncology Unit of Spedali Civili (Brescia, Italy) was also described and included. Sixty-six eligible publications were identified, providing data from one hundred and seventeen patients, plus a case diagnosed at our institution. At presentation, among the eighty-eight patients with symptomatic disease, 37% of patients suffered from abdominal distention and 49% from pain due to a growing abdominal tumor mass, 37% from constipation (peptide YY was analyzed in only nine of them, resulting above the physiologic range). Surgery was the primary therapy in 99% of the patients. Three patients had metastatic disease at diagnosis and five patients underwent recurrence after radical surgery. Histology at disease recurrence concerned the thyroid component in two patients, the carcinoid component in two patients, both histologies in one patient. Median disease-free survival and overall survival in this series were not attained. Strumal carcinoid of the ovary generally presents a benign behavior and surgery is curative in most cases. However, a small group of patients with this disease can undergo disease recurrence due to both the thyroid and the neuroendocrine (carcinoid) components. A follow-up in radically operated patients is therefore needed, particularly in those with a voluminous disease at diagnosis.
Sections du résumé
Background
Ovarian strumal carcinoid is a rare tumor in which thyroid (struma) and carcinoid components coexist. The disease is generally considered to be a borderline malignancy, however, cases with metastatic disease have been described. No data in the literature are available to guide diagnosis and therapy.
Methods
We performed a pooled analysis and a systematic review of histopathological-confirmed strumal carcinoid cases published in the literature using the following keywords: "strumal carcinoid of the ovary", "strumal carcinoid case report". A case of strumal carcinoid tumor diagnosed and followed-up at the Medical Oncology Unit of Spedali Civili (Brescia, Italy) was also described and included.
Results
Sixty-six eligible publications were identified, providing data from one hundred and seventeen patients, plus a case diagnosed at our institution. At presentation, among the eighty-eight patients with symptomatic disease, 37% of patients suffered from abdominal distention and 49% from pain due to a growing abdominal tumor mass, 37% from constipation (peptide YY was analyzed in only nine of them, resulting above the physiologic range). Surgery was the primary therapy in 99% of the patients. Three patients had metastatic disease at diagnosis and five patients underwent recurrence after radical surgery. Histology at disease recurrence concerned the thyroid component in two patients, the carcinoid component in two patients, both histologies in one patient. Median disease-free survival and overall survival in this series were not attained.
Conclusion
Strumal carcinoid of the ovary generally presents a benign behavior and surgery is curative in most cases. However, a small group of patients with this disease can undergo disease recurrence due to both the thyroid and the neuroendocrine (carcinoid) components. A follow-up in radically operated patients is therefore needed, particularly in those with a voluminous disease at diagnosis.
Identifiants
pubmed: 35528006
doi: 10.3389/fendo.2022.871210
pmc: PMC9069053
doi:
Types de publication
Case Reports
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
871210Informations de copyright
Copyright © 2022 Turla, Zamparini, Milione, Grisanti, Amoroso, Pedersini, Cosentini and Berruti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Gynecol Pathol. 1986;5(3):269-77
pubmed: 3759324
Gynecol Oncol. 2002 Oct;87(1):143-5
pubmed: 12468356
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Int J Gynecol Pathol. 2015 Jan;34(1):30-5
pubmed: 25473750
Case Rep Obstet Gynecol. 2012;2012:269489
pubmed: 23029627
J Obstet Gynaecol Res. 2010 Jun;36(3):567-71
pubmed: 20598039
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
Facts Views Vis Obgyn. 2015;7(1):32-41
pubmed: 25897370
Pathology. 2007 Feb;39(1):139-46
pubmed: 17365830
Gynecol Oncol. 1995 Aug;58(2):266-9
pubmed: 7622118
Indian J Pathol Microbiol. 2000 Oct;43(4):459-61
pubmed: 11344613
Eur J Obstet Gynecol Reprod Biol. 2001 Sep;98(1):124-6
pubmed: 11516812
Anticancer Res. 2019 Sep;39(9):5053-5056
pubmed: 31519614
Gynecol Oncol. 1993 Dec;51(3):419-23
pubmed: 8112657
Eur J Gynaecol Oncol. 2011;32(2):201-2
pubmed: 21614915
Histopathology. 2020 Jan;76(1):25-36
pubmed: 31846529
J Obstet Gynaecol Res. 2003 Feb;29(1):28-32
pubmed: 12696624
Int J Gynecol Pathol. 1984;3(2):232-40
pubmed: 6386719
BMJ. 2014 Oct 15;349:g5920
pubmed: 25320247
Medicina (Kaunas). 2020 Dec 11;56(12):
pubmed: 33322438
Endocr Relat Cancer. 2021 Jul 05;28(8):593-604
pubmed: 34105516
Neuroendocrinology. 2012;95(2):120-34
pubmed: 22261872
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Am J Clin Pathol. 1982 May;77(5):622-31
pubmed: 7044103
Cancer Treat Rev. 2017 Sep;59:117-122
pubmed: 28806542
Ann Oncol. 2021 Apr;32(4):439-451
pubmed: 33482246
Arch Pathol Lab Med. 2000 Mar;124(3):477
pubmed: 10705419
Cancer. 1985 Mar 1;55(5):1001-6
pubmed: 3967186
J Obstet Gynaecol Res. 2007 Jun;33(3):392-6
pubmed: 17578375
Int J Gynecol Pathol. 2015 May;34(3):293-7
pubmed: 25760904
Curr Oncol Rep. 2017 Sep;19(9):59
pubmed: 28735441
Histopathology. 1995 Nov;27(5):463-7
pubmed: 8575738
Int J Gynecol Pathol. 1995 Apr;14(2):179-83
pubmed: 8601531
Hum Pathol. 1999 Feb;30(2):242-6
pubmed: 10029457
Cancer. 1980 Nov 1;46(9):2019-34
pubmed: 7427909
Am J Clin Pathol. 1978 Mar;69(3):356-9
pubmed: 637041